{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:21:07Z","timestamp":1794507667551,"version":"4.9.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vomiting, nausea, inappetence, and diarrhea are common delayed adverse effects of doxorubicin. Maropitant, a neurokinin-1 receptor antagonist, is known to prevent acute vomiting in dogs receiving cisplatin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy of maropitant in preventing delayed vomiting after administration of doxorubicin to dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Fifty-nine dogs with cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This randomized, double-blind, placebo-controlled study used a cross-over design. Dogs were randomized into 1 of 2 treatment groups. Group A received maropitant after the 1st doxorubicin, and placebo after the 2nd. Group B received placebo first, and maropitant second. Maropitant (2\u2003mg\/kg) or placebo tablets were administered PO for 5 days after doxorubicin treatment. Owners completed visual analog scales based on Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events to grade their pet's clinical signs during the week after administration of doxorubicin. Statistical differences in gastrointestinal toxicosis and myelosuppression between maropitant and placebo treatments were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Significantly fewer dogs had vomiting (P= .001) or diarrhea (P= .041), and the severity of vomiting (P &amp;lt; .001) and diarrhea (P= .024) was less the week after doxorubicin when receiving maropitant compared with placebo. No differences were found between maropitant and placebo for other gastrointestinal and bone marrow toxicoses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Maropitant is effective in preventing delayed vomiting induced by doxorubicin. Its prophylactic use might improve quality of life and decrease the need for dose reductions in certain dogs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1939-1676.2010.0611.x","type":"journal-article","created":{"date-parts":[[2010,10,12]],"date-time":"2010-10-12T18:57:41Z","timestamp":1286909861000},"page":"1452-1457","source":"Crossref","is-referenced-by-count":49,"title":["Efficacy of Maropitant in the Prevention of Delayed Vomiting Associated with Administration of Doxorubicin to Dogs"],"prefix":"10.1093","volume":"24","author":[{"given":"S.E.","family":"Rau","sequence":"first","affiliation":[{"name":"Harrington Oncology Program, Cummings School of Veterinary Medicine, Tufts University , North Grafton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.G.","family":"Barber","sequence":"additional","affiliation":[{"name":"Harrington Oncology Program, Cummings School of Veterinary Medicine, Tufts University , North Grafton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.E.","family":"Burgess","sequence":"additional","affiliation":[{"name":"Harrington Oncology Program, Cummings School of Veterinary Medicine, Tufts University , North Grafton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,11,1]]},"reference":[{"key":"2026020303181224200_b1","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.2460\/javma.1989.195.11.1580","article-title":"Phase II evaluation of doxorubicin for treatment of various canine neoplasms","volume":"195","author":"Ogilvie","year":"1989","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303181224200_b2","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2460\/javma.1995.206.10.1555","article-title":"Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma","volume":"206","author":"Berg","year":"1995","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303181224200_b3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1939-1676.1996.tb02085.x","article-title":"Surgery and doxorubicin in dogs with hemangiosarcoma","volume":"10","author":"Ogilvie","year":"1996","journal-title":"J Vet Intern Med"},{"key":"2026020303181224200_b4","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2460\/javma.1989.195.11.1584","article-title":"Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors","volume":"195","author":"Ogilvie","year":"1989","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303181224200_b5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2165\/00003495-200969050-00002","article-title":"Pharmacological management of chemotherapy-induced nausea and vomiting","volume":"69","author":"Navari","year":"2009","journal-title":"Drugs"},{"key":"2026020303181224200_b6","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1365-2885.2007.00877.x","article-title":"The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs","volume":"30","author":"Benchaoui","year":"2007","journal-title":"J Vet Pharmacol Therap"},{"key":"2026020303181224200_b7","first-page":"569","article-title":"Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis","volume":"24","author":"Navari","year":"2004","journal-title":"Summary of clinical trials"},{"key":"2026020303181224200_b8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1476-5829.2006.00123.x","article-title":"Efficacy of injectable maropitant (Cerenia) in a randomized clinical trial for prevention and treatment of cisplatin induced emesis in dogs presented as veterinary patients","volume":"5","author":"Vail","year":"2007","journal-title":"Vet Comp Oncol"},{"key":"2026020303181224200_b9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2460\/ajvr.68.1.48","article-title":"Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs","volume":"68","author":"De la Puente-Redondo","year":"2007","journal-title":"Am J Vet Res"},{"key":"2026020303181224200_b10","first-page":"2932","article-title":"American society of clinical oncology guideline for antiemetics in oncology","volume":"24","author":"Kris","year":"2006","journal-title":"Update 2006"},{"key":"2026020303181224200_b11","first-page":"141","article-title":"Freedom of information summary","author":"Food and Drug Administration.","year":"2007","journal-title":"Cerenia (maropitant citrate) injectable solution for the prevention and treatment of acute vomiting in dogs"},{"key":"2026020303181224200_b12","first-page":"194","article-title":"A consensus document from the VCOG","volume":"2","author":"Veterinary Co-operative Oncology Group Common Terminology Criteria for Adverse Events (VCOG-CTCAE).","year":"2004","journal-title":"Vet Comp Oncol"},{"key":"2026020303181224200_b13","first-page":"23","article-title":"Immunomodulatory properties of substance P","volume":"1088","author":"Koon","year":"2006","journal-title":"The gastrointestinal tract as a model"},{"key":"2026020303181224200_b14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0163-7258(96)00195-7","article-title":"Tachykinins in the gut. Part I. Expression, release and motor function","volume":"73","author":"Holzer","year":"1997","journal-title":"Pharmacol Ther"},{"key":"2026020303181224200_b15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0163-7258(96)00196-9","article-title":"Tachykinins in the gut. Part II. Roles in neural excitation, secretion and inflammation","volume":"73","author":"Holzer","year":"1997","journal-title":"Pharmacol Ther"},{"key":"2026020303181224200_b16","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)64789-X","article-title":"Substance P (neurokinin-1) and neurokinin A (neurokinin-2) receptor gene and protein expression in the healthy and inflamed human intestine","volume":"157","author":"Renzi","year":"2000","journal-title":"Am J Pathol"},{"key":"2026020303181224200_b17","first-page":"68","article-title":"Substance P receptor expression in intestinal epithelium in Clostridium difficile toxin A enteritis in rats","volume":"275","author":"Pothoulakis","year":"1998","journal-title":"Am J Physiol"},{"key":"2026020303181224200_b18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/jcp.20061","article-title":"The role of substance P in inflammatory disease","volume":"201","author":"O'Connor","year":"2004","journal-title":"J Cell Physiol"},{"key":"2026020303181224200_b19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0031-6997(25)06575-5","article-title":"Substance P","volume":"35","author":"Pernow","year":"1983","journal-title":"Pharmacol Rev"},{"key":"2026020303181224200_b20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1046\/j.1365-201X.1996.457174000.x","article-title":"Tachykinins increase vascular permeability in the gastrointestinal tract of the rat","volume":"156","author":"Lordal","year":"1996","journal-title":"Acta Physiol Scand"},{"key":"2026020303181224200_b21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1086\/376836","article-title":"Substance P expression correlates with severity of diarrhea in Cryptosporidiosis","volume":"188","author":"Robinson","year":"2003","journal-title":"J Infect Dis"},{"key":"2026020303181224200_b22","first-page":"176","article-title":"Immunocytochemical localization of vasoactive intestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease","volume":"87","author":"Mazumdar","year":"1992","journal-title":"Am J Gastroenterol"},{"key":"2026020303181224200_b23","first-page":"613","article-title":"Neurokinin 1 receptor antagonists\u2014current prospects","volume":"10","author":"Alvaro","year":"2007","journal-title":"Curr Opin Drug Discov Devel"},{"key":"2026020303181224200_b24","first-page":"333","article-title":"Treatment with neurokinin-1 receptor antagonist reduces severity of inflammatory bowel disease induced by Cryptosporidium parvum","volume":"9","author":"Sonea","year":"2002","journal-title":"Clin Diagn Lab Immunol"},{"key":"2026020303181224200_b25","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1645\/GE-1458.1","article-title":"Substance P receptor antagonism for treatment of cryptosporidiosis in immunosuppressed mice","volume":"94","author":"Robinson","year":"2008","journal-title":"J Parasitol"},{"key":"2026020303181224200_b26","first-page":"1346","article-title":"Human colonic anti-secretory activity of the potent NK1 antagonist, SR140333","volume":"133","author":"Moriarty","year":"2001","journal-title":"Assessment of potential anti-diarrhoeal activity in food allergy and inflammatory bowel disease"},{"key":"2026020303181224200_b27","first-page":"187","article-title":"Chemotherapy-induced nausea and vomiting","volume":"8","author":"Schnell","year":"2003","journal-title":"The importance of acute antiemetic control"},{"key":"2026020303181224200_b28","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/ajhp\/56.8.729","article-title":"ASHP Commission on Therapeutics. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery","volume":"56","year":"1999","journal-title":"Am J Health Syst Pharm"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1939-1676.2010.0611.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/24\/6\/1452\/66655275\/j.1939-1676.2010.0611.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/24\/6\/1452\/66655275\/j.1939-1676.2010.0611.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:18:23Z","timestamp":1770106703000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/24\/6\/1452\/8447465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,1]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1939-1676.2010.0611.x","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,11]]},"published":{"date-parts":[[2010,11,1]]}}}